WO2016108400A2 - Composition for skin, containing lonicera caerulea fruit extracts as effective ingredient - Google Patents

Abstract

The present invention relates to a cosmetic composition for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing, a pharmaceutical composition for skin regeneration or skin whitening, and an over the counter product for skin improvement, the composition containing Lonicera caerulea fruit extract as an effective ingredient.

Description

Skin composition containing Taraxacum berry extract as an active ingredient

The present invention is a dagger ( Lonicera) caerulea ) The present invention relates to a skin composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing cosmetic composition, a pharmaceutical composition for skin regeneration or skin whitening, and a quasi-drug for skin improvement.

Skin is the body's primary protective film that protects organs in the body from stimulation of the external environment such as temperature and humidity changes, ultraviolet rays and pollutants, and plays an important role in maintaining homeostasis such as body temperature control. This important skin, like other organs of the human body, gradually ages as the body ages. As a result, skin elasticity loss, keratinization, wrinkle formation, and skin atrophy occur.

Many studies have been conducted on the importance and role of collagen directly affecting wrinkles and skin elasticity. When collagen, which accounts for most of the skin, 77% of the skin, and 90% of the dermis, is quantitatively rich and qualitatively healthy, the skin can also remain healthy and beautiful without wrinkles and sagging. Conventionally, collagen was sometimes formulated into cosmetic products, but when collagen is applied to the skin surface as a cosmetic product, there is a problem in that the percutaneous absorption of collagen, which is a polymer, is difficult, and its function cannot be sufficiently expected.

On the other hand, as a pigment present in the epidermal layer of the skin, melanin is made from melanocytes (melanocyte) present in the basal layer of the epidermis and migrates to epidermal cells called keratinocytes.

Depending on the production of such melanin can cause a variety of diseases. If melanin accumulates due to excessive synthesis or melaninization due to excessive sunlight, hormonal changes, inflammation, or drugs, it not only damages the skin but also deposits pigments on the skin, forming spots and freckles. It can also lead to skin cancer from the same lesion. Therefore, in order to prevent such a pigmentation phenomenon, it is necessary to inhibit a part of the melanin production process to reduce melanin production.

On the other hand, the development of a whitening agent for the treatment of abnormal skin pigmentation and to meet the beauty needs are actively made. At present, in the development of a whitening agent for skin beauty, a method of reducing the generated melanin pigment by decolorization and a method of inhibiting the activity of tyrosinase, an enzyme that forms melanin pigment, are known. In the conventional cosmetic field, as a whitening component, for example, substances that inhibit tyrosinase enzyme activity such as kojic acid, arbutin, hydroquinone, vitamin C, and derivatives thereof and various plant extracts This has been used. However, the whitening components are degraded due to poor stability in the formulation, or the use thereof is limited due to the occurrence of off-flavor, efficacy at the biological level, unclear effect and stability problems.

On the other hand, the skin has a barrier function that protects the body from various external stimuli and at the same time prevents moisture from inside. However, people tend to increase dry skin as they age, especially, as women age, their sebum secretion is not smooth due to decreased secretion of the female hormone estrogen. There is a tendency to lead to aging.

Also, in general, environmental pollution is severe and the skin is easily damaged by the increase of UV irradiation amount due to destruction of ozone layer, drying of living space, allergic constitution of individual, stress, and increase of chemical harmful substances. It is happening that the skin is easily reddened or sensitive. Recently, a study resulted in abnormal expression of protein in skin due to heat applied to the skin and skin sagging due to aging due to free radicals and degradation of elastic fibers (JJ 10-2006-0113112). Invest.Dermatol. 124, 70-78, 2005).

As such, various cosmetic compositions using various moisturizers such as oils, sugars, and polyols have been developed to improve dryness of the skin due to an increase in UV irradiation amount, drying of living spaces, stress, and chemical harmful substances. For example, by using the skin components such as ceramide, cholesterol, fatty acids, etc., the skin barrier function is strengthened to suppress moisture evaporating from the skin, or sugar, polyol, etc., which has a strong ability to bind with water on the surface of the skin, thereby improving skin moisture retention ability. To enhance the moisturizing effect of the skin. However, in the winter when the relative humidity is low, it is difficult to sustain the effect for a long time, and in the summer when the relative humidity is high, rather uncomfortable, there is a difficulty in producing a proper cosmetic composition according to the change in the relative humidity.

On the other hand, Lonicera caerulea ) fruit has been used in folk medicine in North Russia, China, and Japan, but little is known as an edible fruit in North America, Europe, and Korea, and it is used to prevent skin aging, skin regeneration, skin wrinkle improvement, skin whitening, or There is no known skin moisturizing effect.

The present inventors have made efforts to develop a composition that is excellent in stability and effective in skin beauty and skin-related diseases, and as a result, the Rootberry Extract is used for skin aging, skin regeneration, skin wrinkle improvement, skin whitening, and skin moisturizing. The present invention was completed by confirming that it can be usefully used for skin care and skin-related diseases.

One object of the present invention, the dagger ( Lonicera caerulea ) to provide a cosmetic composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing fruit extract as an active ingredient.

Another object of the present invention to provide a pharmaceutical composition for skin regeneration or skin whitening containing the extract as an active ingredient.

Still another object of the present invention is to provide a quasi-drug for skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing the extract as an active ingredient.

Another object of the present invention to provide a health functional food composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing the extract as an active ingredient.

Another object of the present invention is to provide a method for preventing skin aging, comprising administering the extract to a subject.

Another object of the present invention is to provide a method for regenerating skin, comprising administering the extract to a subject.

Another object of the present invention is to provide a method for improving skin wrinkles, comprising administering the extract to a subject.

Still another object of the present invention is to provide a method for skin whitening, comprising administering the extract to a subject.

Still another object of the present invention is to provide a method of moisturizing skin, comprising administering the extract to a subject.

The composition containing the Taraxacum fruit extract of the present invention as an active ingredient can be used as a cosmetic composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing.

1A-1C The effect of BHcL (FIG. 1A), LFs (FIG. 1B) and LFi (FIG. 1C) on human fibroblast viability is shown. Cells were treated with 0 (control), 1.25, 2.5, 5, 10, 100 and 500 mg / ml of BHcL, LFs or LFi and incubated for 24 hours, followed by MTT treatment for an additional 4 hours. Each value represents the mean ± SD value of five independent experiments.

2A-2C show the effects of BHcL (FIG. 2A), LFs (FIG. 2B) and LFi (FIG. 2C) on B16 / F10 murine melanoma cell viability. Cells were treated with 0 (control), 1.25, 2.5, 5, 10, 100 and 500 mg / ml of BHcL, LFs or LFi and incubated for 24 hours, followed by MTT treatment for an additional 4 hours. Each value is ± the mean of five independent experiments Indicates SD value.

3A-3D show the effects of TGF-β1 (FIG. 3A), BHcL (FIG. 3B), LFs (FIG. 3C) and LFi (FIG. 3D) on fibroblast collagen type I synthesis. EC ₅₀ represents the concentration when the percentage of collagen type I synthesis is 200%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01: compared to control with LSD test, ^b p <0.01 and ^c p <0.05: compared with EC ₅₀ of BHcL with LSD test.

4A-4D show the hyaluronidase inhibitory activity of OA (FIG. 4A), BHcL (FIG. 4B), LFs (FIG. 4C) and LFi (FIG. 4D). IC ₅₀ represents the concentration when the percentage of hyaluronidase activity is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01 and ^b p <0.05: compared to control with LSD test, ^c p <0.01 and ^d p <0.05: compared to control with MW test, ^e p <0.01: compared to IC50 of BHcL with MW test.

5A-5D show the elastase inhibitory activity of PP (FIG. 5A), BHcL (FIG. 5B), LFs (FIG. 5C) and LFi (FIG. 5D). IC ₅₀ represents the concentration when the percentage of elastase activity is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01: compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.

6A-6D show collagenase inhibitory activity of OA (FIG. 6A), BHcL (FIG. 6B), LFs (FIG. 6C) and LFi (FIG. 6D). IC ₅₀ represents the concentration when the percentage of collagenase activity is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01: compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.

7A-7D show MMP-1 inhibitory activity of OA (FIG. 7A), BHcL (FIG. 7B), LFs (FIG. 7C) and LFi (FIG. 7D). IC ₅₀ represents the concentration when the percentage of MMP-1 activity is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01: compared to control with LSD test, ^b p <0.01: compared to control with MW test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.

8A-8D show tyrosinase inhibitory activity of arbutin (FIG. 8A), BHcL (FIG. 8B), LFs (FIG. 8C) and LFi (FIG. 8D). IC ₅₀ represents the concentration when the percentage of tyrosinase activity is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01 and ^b p <0.05: compared to control with LSD test, ^c p <0.01: compared to control with MW test, ^d p <0.01: compared to IC ₅₀ of BHcL with MW test.

9A to 9D show melanin formation inhibitory activity of arbutin (FIG. 9A), BHcL (FIG. 9B), LFs (FIG. 9C) and LFi (FIG. 9D). IC ₅₀ represents the concentration when the melanin production percentage is 50%. Each value represents the mean ± SD value of five independent experiments. ^a p <0.01 and ^b p <0.05: compared to control with LSD test, ^c p <0.01: compared to IC ₅₀ of BHcL with MW test.

Figure 10 confirms the skin moisture content of mice treated with BHcL, LFs or LFi untreated. Each value represents the mean ± SD value of five mouse skins. ^a p <0.01 and ^b p <0.05: untreated control with MW test, ^c p <0.01 and ^d p <0.05: compared with skin treated with LFs 0.167 mg / cm ² with MW test, ^e p <0.01: MW test Skin treated with LFi 0.167 mg / cm ² .

As one aspect for achieving the above object, the present invention provides a cosmetic composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or moisturizing skin containing Lonicera caerulea fruit extract as an active ingredient. .

In the present invention, "Longera ( Lonicera) caerulea ) is a dicotyledonous plant of the locust tree, which is a deciduous shrub reaching 1.5m in height, with many branched branches, shield-shaped bracts on the branches of small branches, and the inner part of the tree trunk is white. Flowers are oval or elliptical, blunt or sharp at both ends, no sawtooth, short hairs on the edges and surfaces, villi on the back, flowers usually have short peduncles, run on the axillas, and the ferns are pale yellow-white and bloom in summer. Calyxes are divided into five like crabs, corollas are yellowish white, cylindrical bells, 1.2-1.5cm long, with some hairs, and stamens are shorter than pistils, without hairs, and two of them are combined. Is a cold plant found in Siberia, Sakhalin, northern China, Tibet, and North Korea.

The fruit of the Taraxacum is oval or almost round, ripened in purple and covered with white powder in July-August. In the pharmacological activity of the tree, the prevention and treatment of diseases such as hepatitis, liver cirrhosis or fatty liver, and the hangover removal effect of the fruit of the tree is known, but the thyroid function of the fruit of the tree There is no known use for the prophylaxis or treatment of thyroid diseases such as hypothyroidism, hyperthyroidism, thyroiditis or thyroid nodules and was first identified by the inventors. Taraxacum fruit in the present invention can be purchased commercially, or can be used collected or grown in nature.

In the present invention, the "Rangberry fruit extract" refers to all obtained by extracting from the Baeng fruit. The Root fruit extract may be obtained by extracting the Root fruit extract by using water, an organic solvent, or a mixed solvent thereof, and may include an extract, a dry powder thereof, or any form formulated using the extract. have. In addition, in the extraction method, hot water extraction, cold extraction, reflux extraction or ultrasonic extraction may be used, but is not limited thereto. In the present invention, the dagger fruit extract is used in combination with BHcL.

In obtaining the Taraxacum fruit extract, it may be preferably extracted using water, an organic solvent or a mixed solvent thereof.

Extraction using an organic solvent is not limited thereto, and specific examples include methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylform Amide (DMF), dimethylsulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used, and at room temperature or warmed under conditions where the active ingredient of the crude drug is not destroyed or minimized. Can be extracted. Depending on the organic solvent to be extracted, the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.

The solvent extract may further comprise filtering the extract to remove suspended solid particles. Particles may be filtered out using cotton or nylon, or ultrafiltration, freezing, centrifugation, or the like may be used, but is not limited thereto.

Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration. The drying step after the concentration includes, but is not limited to, lyophilization, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, or infrared drying. In some cases, the method may further include grinding the final dried extract.

In addition, the extract can perform an additional fractionation process. For example, the extract is suspended in distilled water to extract and separate a nonpolar solvent soluble layer with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate or a mixed solvent thereof. Concentrated and / or dried may be used.

As a specific example, 5 to 25 times, preferably 7 to 15 times, water of 1 to 5 times the carbon number (C ₁ ) to 4 (C) of the dry weight (kg) of the wood to provide the extract Lower alcohol of ₄ ) or a mixed solvent thereof, preferably water or a mixed solvent of water and ethyl alcohol; At an extraction temperature of 20 to 100 ° C., preferably 60 to 100 ° C .; 0.5 hour to 2 days, preferably 1 hour to 1 day; Hot water extraction, cold extraction, ultrasonic extraction, reflux extraction, preferably by reflux extraction; It can be obtained by continuous extraction from 1 to 5 times, preferably 2 to 3 times. In addition, the extract is filtered through the filter and the filtrate is concentrated under reduced pressure at 20 to 100 ℃, preferably 50 to 70 ℃ with a rotary vacuum concentrator, and then dried to prepare a powder of the powdered dagger fruit. The powdered Daengdu fruit extract can be used as is or dissolved in a certain concentration in a solvent. However, it is not limited to the above example.

According to a specific embodiment of the present invention, the Tarmac extract may be used for skin aging prevention, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing.

As used herein, the term "anti-aging of skin" refers to preventing or delaying degeneration of skin tissue due to physiological changes of the body over time. In order to prevent skin aging, the skin must be protected from the harmful environment as well as moisture is properly supplied to the skin, and the skin cells are activated to promote the synthesis of biosynthetic proteins such as collagen and elastin. The formation of wrinkles should be suppressed as much as possible. In particular, the collagen and elastic fibers of elastin form a network structure in the dermal layer. As the network structure is broken, the elastin is broken down by the enzyme delase, alastase, which causes the skin to swell and wrinkle. As a result, endogenous skin aging occurs. Therefore, the degradation of elastin, which is one of the main causes of skin aging, can be suppressed to inhibit skin aging.

As used herein, the term "skin regeneration" refers to the process of recovery of skin tissue against damage by external and internal causes of the skin. The damage caused by the external causes may include ultraviolet rays, external pollutants, wounds, traumas, and the like, and the damage caused by the internal causes may include stress.

As used herein, the term "improvement of skin wrinkles" means maintaining or enhancing the wrinkles and elasticity of the skin. Collagen (collagen) and elastic fiber elastin (collagen) in the dermal layer of the skin control the skin elasticity as a major protein that plays a role, and thus has an inhibitory effect on the secreting elastase and / or collagenase activity In the case of wrinkles can be improved.

The term "skin whitening" of the present invention refers to the function of preventing melanin pigments from increasing in the skin and thereby excessively depositing melanin pigments on the skin, or thinning of previously deposited melanin pigments. As a result, it is possible to suppress the production of blemishes and freckles caused by excessive deposition of melanin pigment.

The term “skin moisturizing” means to form a film on the skin that will enhance the skin's ability to retain the moisture already present in the skin.

Taraxacum fruit extract of the present invention promotes the synthesis of collagen type I, inhibits hyaluronidase, elastase, collagenase and / or MMP-1 to prevent skin aging , Skin regeneration and anti-wrinkle effect. In addition, the extract may exhibit a whitening effect by inhibiting tyrosinase and inhibiting melanin formation in melanoma. Furthermore, the extract may exhibit a moisturizing effect.

In conclusion, the cosmetic composition containing the Root fruit extract of the present invention as an active ingredient may exhibit an excellent effect on preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening and / or skin moisturizing.

In the present invention, the above-mentioned dagger fruit extract may be included in an appropriate amount to achieve the above-described effect.

In addition, the cosmetic composition according to the present invention, in addition to the above-mentioned dagger fruit extract, various components generally used in the external preparation for skin within the range of not lowering the effect of the present invention, if necessary, for example, water-soluble components, powder components, oil, It may be configured by combining a surfactant, a moisturizer, a viscosity modifier, a preservative, an antioxidant, a perfume, a dye, and the like.

The formulation of the cosmetic composition according to the present invention can be arbitrarily selected, together with the extract of the fruit of the tree, the active ingredient, water, saline, glycerol, oil, surfactants, moisturizers, thickeners, chelating agents, pigments, preservatives and fragrances, etc. Known cosmetic excipients are mixed to form cosmetic compositions in the form of lotions, liquids, emulsions, emulsions, suspensions, tablets and capsules. The cosmetic composition may be used to prepare basic cosmetics such as flexible lotion, milk lotion, nourishing cream, massage cream, essence, cleansing foam, cleansing water, pack or body oil, and color cosmetics such as foundation, lipstick, mascara or makeup base. It may also prepare face washes and baths.

In order to promote the absorption and fixation of the extract of the fruit tree of such a cosmetic composition, glycerin 1-7% by weight is included in the cosmetic excipient, the composition of the powder of the fruit of the tree extract, but is not limited thereto.

In addition, sunflower oil may be included in the cosmetic excipient to provide an antioxidant function to the cosmetic composition, but is not limited thereto.

In another aspect, the present invention provides a sapling ( Lonicera) caerulea ) Provides a pharmaceutical composition for skin regeneration or skin whitening containing fruit extract as an active ingredient.

Dandelion fruit extract, skin regeneration and skin whitening are as described above.

The composition of the present invention may promote the synthesis of collagen type I, inhibit hyaluronidase, elastase, collagenase and / or MMP-1, and Because it can inhibit tyrosinase and inhibit the formation of melanin in melanoma, it can be used as a pharmaceutical composition for skin regeneration and skin whitening.

The skin regeneration effect may be used to treat wounds, and the skin whitening effect may be used for the prevention or treatment of diseases such as melanoma, blemishes, and freckles that require melanin reduction.

The throughput of the pharmaceutical composition for skin regeneration or skin whitening used in the present invention should be a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level may refer to an individual type and severity, age, sex, The type of disease, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, the factors including the drug used concurrently, and other factors well known in the medical art can be determined. Effective amounts may vary depending on the route of treatment, the use of excipients, and the possibility of use with other agents, as will be appreciated by those skilled in the art.

Pharmaceutical compositions for skin regeneration or skin whitening of the present invention may be prepared in pharmaceutical formulations using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.

Therefore, the pharmaceutical compositions of the present invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations and patches according to a conventional method, the composition It may further comprise suitable carriers, excipients or diluents commonly used in the preparation of the compounds.

For example, carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, weights, binders, wetting agents, disintegrating agents and surfactants are usually used.

In another aspect, the present invention is a dagger ( Lonicera) caerulea ) Provides quasi-drugs for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing fruit extract as an active ingredient.

Dandelion fruit extract, anti-aging skin, skin regeneration, skin wrinkle improvement, skin whitening and skin moisturizing are as described above.

As used herein, the term "quasi drug" refers to a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide, and similar purposes for the prevention of infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases. Among articles to be used, which are not instruments, machines or devices, and articles which are used for the purpose of pharmacologically affecting the structure and function of humans or animals, except those which are not instruments, machines or devices. Also includes supplies.

The external preparation for skin is not particularly limited thereto, but may be preferably used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel. The personal hygiene article is not particularly limited, but preferably soap, cosmetics, wet wipes, tissue paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, makeup, foundation, ball touch, mascara, eye shadow, sunscreen lotion , Hair care products, air freshener gel or cleaning gel. In addition, another example of the quasi-drug composition of the present invention is a disinfectant cleaner, shower foam, gagreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.

In another aspect, the present invention is a dagger ( Lonicera) Caerulea ) provides a health functional food composition for preventing skin aging, skin regeneration, skin wrinkle improvement, skin whitening or skin moisturizing containing fruit extract as an active ingredient.

Dandelion fruit extract, anti-aging skin, skin regeneration, skin wrinkle improvement, skin whitening and skin moisturizing are as described above.

When the composition of the present invention is used as a nutraceutical additive, the composition may be added as it is or used with other nutraceutical or nutraceutical ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the intended use. In general, the composition of the present invention may be added in the amount of preferably 15 parts by weight or less, more preferably 10 parts by weight or less based on the raw material in the manufacture of food or beverage. However, in the case of long-term intake for the purpose of health control and hygiene, the amount may be below the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount above the above range.

There is no particular limitation on the type of dietary supplement of the present invention. Examples of health functional foods to which the composition can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, Drinks, alcoholic beverages and vitamin complexes, and the like, may include all of the health functional foods in the conventional sense, may include foods used as feed for animals.

In addition, when the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweetening agents, flavoring agents or natural carbohydrates, etc. as additional ingredients, as in the usual beverage. The natural carbohydrate can be glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweetener may be a natural sweetener such as taumartin, stevia extract and a synthetic sweetener such as saccharin, aspartame.

In addition to the above, the nutraceutical composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.

In another aspect, the present invention is a dagger ( Lonicera) caerulea ) provides a method for preventing skin aging, a method for regenerating the skin, a method for improving skin wrinkles, a method for skin whitening, and a method for moisturizing the skin, comprising administering to the subject a caerulea fruit extract.

In another aspect, the present invention is the Dacha ( Lonicera) caerulea ) provides a wound treatment and skin regeneration treatment method comprising administering to the damaged skin a pharmaceutical composition comprising a fruit extract as an active ingredient.

In the present invention, the term "treatment" refers to any action that the wound or skin regeneration is improved or beneficially changed by administration of the composition.

The method of treatment using the Root fruit extract of the present invention includes administering the Root fruit extract to the damaged skin. It will be apparent to those skilled in the art that a suitable total daily dose may be determined by the practitioner within the correct medical judgment. It may also be administered once or in divided doses. However, for the purposes of the present invention, the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medical field, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or co-specific with the specific composition.

Individuals to which the composition of the present invention is administered include, but are not limited to, mammals including humans, for example cattle, pigs, horses, rabbits, mice, and humans.

As used herein, the term "administration" means introducing a pharmaceutical composition of the present invention to a patient in any suitable manner, and the route of administration of the composition of the present invention is not particularly limited, but reaches the desired damaged skin tissue. Administration may be via a variety of routes to do so.

According to one aspect of the present invention, the present invention provides a use of the Taraxacum fruit extract for the preparation of a composition for preventing skin aging, skin regeneration, skin wrinkle improvement, or skin moisturizing. The composition for preventing skin aging, skin regeneration, skin wrinkle improvement or skin moisturizing is not particularly limited, but is preferably a pharmaceutical composition or cosmetic composition for skin aging prevention, skin regeneration, skin wrinkle improvement, or skin moisturizing.

Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are only intended to illustrate the invention and are not to be construed as limiting the scope of the invention by these examples.

Comparative example  One. Comparative Example  Produce

Lonicerae Flos ) and Lonicerae Folium were purchased from Omniherb (Yeoungcheon, Korea). A total of 500 g of dried sterling silver or phosphorus was boiled three times for 3 hours at 60 ° C. for 3 hours in 5,000 ml of distilled water, evaporated and completely lyophilized under reduced pressure. A total of 119.00 g (yield = 23.8%) of sterling silver extracts (LFs) and 113.5 g (yield = 22.7%) of phosphorous extracts (LFi) were obtained.

Example  1. Experimental Materials

Arbutin powder (Sigma-Aldrich, St. louise, MO, USA), TGF-β1 powder (R & D System, Minneapolis, MN, USA), solid PP (Phosphoramidon disodium salt; Sigma, St. Louise, MO, USA) USA), and solid OA (Oleanolic acid; Sigma, St. Louise, MO, USA) were used as positive controls for skin regeneration, anti-wrinkle or whitening effects, respectively.

Example  2. Wood  Lychee extract manufacturer

63 brix of Lonicera caerulea ) 200 g of fruit concentrate was diluted to 25 brix with distilled water, and then lyophilized under a reduced pressure using a programmable lyophilizer (Operon FDB-5503, Kimpo, Korea), totaling 124.40 g (yield = 62.2%) Tree fruit extract (BHcL) was obtained. Component analysis confirmed that the BHcL was 380 kcal / 100 ml of energy, 93 g / 100 ml of carbohydrate, 41 g / 100 ml of sugar, 2 g / 100 ml of protein, 200 mg / 100 ml of sodium, and total lipid, saturated lipid, trans fat and It does not contain cholesterol. Furthermore, the BHcL is 4.54 ± 0.09% of betaine, 210.63 ± 23.65 mg of gallic acid equivalent per g of phenol, and catechin equivalent per g of flavonoids by photochemical analysis. 159.30 ± 12.51 mg, and 133.57 ± 4.06 mg of M3GE (malvidin-3-O-glucoside equivalent) per g total anthocyanin.

Example  3. Cytotoxicity Assay

Human fibroblasts (CRL-2076; ATCC, Manassas, VA, USA) and B16 / F10 murine melanoma cells (CRL-6475; ATCC, Manassas, VA, USA) were 37 ° C., 5% CO ₂ Conditions were 10% FBS (Gibco BRL, Grand Island, NY, USA), 100 units / ml penicillin (Sigma-Aldrich, St. Louise, MO, USA) and 100 μg / ml streptomycin (Sigma-Aldrich, St. Louise) And cultured in DMEM (Dulbecco's Modified Eagle's Medium; Sigma-Aldrich, St. Louise, MO, USA) medium containing. Fresh medium was replaced every two or three days and 0.05% trypsin-0.53 mM EDTA (Sigma-Aldrich, St. Louise, Mo., USA) was used for subculture. For B16 / F10 murine melanoma cells, additional 2 mM L-glutamine (Sigma-Aldrich, St. Louise, Mo., USA) was added to the medium. The cells were seeded in 24-well plates at 1 × 10 ⁵ cells per well and incubated at 37 ° C., 5% CO ₂ conditions. The next day, replace with fresh medium containing 2% serum, incubate for 24 hours in the conditions with each sample (1.25, 2.5, 5, 10, 100 and 500 mg / ml), then 2.5 mg / ml MTT 100 μl (Sigma-Aldrich, St. Louise, Mo., USA) was treated. The cells were then incubated for an additional 4 hours. Then, the medium was removed and the produced MTT formazan was extracted with 1 ml of DMSO. Absorbance was measured on a microplate reader (Tecan, Mannedorf, Switzerland) at 570 nm (test wavelength) and 650 nm (reference wavelength). Cell viability was calculated by the following formula [1].

Formula [1]. Cell survival rate (%)

= OD ₅₇₀ (sample) / OD ₅₇₀ (control) x100, where OD ₅₇₀ (sample) is the absorbance at 570 nm of the sampled cells and OD ₅₇₀ (control) is the absorbance at 570 nm of the untreated cells.

Example  4. Skin anti aging, skin regeneration and Hangzhou wrinkle  effect

Anti-aging, skin regeneration and anti-wrinkle effects of the test specimens in the present invention are confirmed through collagen type I synthesis analysis and inhibition of hyaluronidase, elastase, collagenase and MMP-1 It was.

(1) EIA Kit  Collagen Type I Synthesis Assay

Fibroblasts were seeded in 24-well plates ( ⁵ × 10 ⁵ cells / well) and incubated for 24 hours. Subsequently, replace the medium with serum-free IMDMve's modified Dulbecco's medium (Sigma-Aldrich, St. Louise, MO, USA) and test samples (BHcL, LFs) at 0.0125, 0.025, 0.05, 0.1, 1 or 10 mg / ml. And LFi) or 0.1, 1, 10, 20, 40 or 100 ng / ml of TGF-β1 and incubated for 24 hours. Controls were incubated without compound addition. After incubation, the medium is collected from each well, and the amount of pro-collagen type I is measured at 450 nm in a microplate reader using a pro-collagen type IC peptide assay kit (Takara Bio, Tokyo, Japan). It was. Pro-collagen synthesis was calculated by the following formula [2] and the results are expressed as EC ₅₀ (concentration when the percentage of collagen type I synthesis is 200%).

Formula [2]. Pro-collagen synthesis (%)

= OD ₄₅₀ (sample) / OD ₄₅₀ (control) × 100, where OD ₄₅₀ (sample) is the absorbance at 450 nm of the cells that processed the sample, and OD ₄₅₀ (control) at ₄₅₀ nm of the untreated cells Absorbance

(2) hyaluronidase ( hyaluronidase ) Inhibition assay

Hyaluronidase reacts with hyaluronic acid, a substrate, to release N-acetyl glucosamine. In the presence of an inhibitor, the release of N-acetyl glucosamine was reduced and observed by measuring 600 nm absorbance. Inhibitory activity of BHcL, LFs or LFi (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml) was compared with standard OA under exactly the same experimental conditions. The 600 nm value of undecomposed hyaluronic acid was made into 100%. After 15 minutes of treatment, OD values were measured at 600 nm with a 96-well microplate reader (Tecan, Mannedorf, Switzerland), and the hyaluronidase inhibitory activity of each sample was calculated by the following formula [3].

Formula [3]. Hyaluronidase Inhibitory Activity (%)

= 100-{[(ODs + ODc) / ODc] × 100}, where ODs is the absorbance at 600 nm of the test specimen and ODc is the absorbance at 600 nm of the untreated control.

The results are expressed as IC ₅₀ (concentration when the hyaluronidase activity inhibition rate is 50%).

(3) elastase ( elastase ) Inhibition assay

Human leukocyte elastase (Sigma-Aldrich, St. Louise, Mo., USA) is responsible for N-succinyl- (Ala) 3-p-nitroanilide (N-succinyl- (Ala) 3-p-nitroanilide). As it decomposes, p- under conditions with or without BHcL (12.5, 25, 50, 100, 200 and 400 μg / ml) or with the addition of PP (0.625, 1.25, 2.5, 5, 10 and 100 ng / ml) as standard. Elastase inhibition assays were performed by measuring the release of nitroaniline. The absorbance was measured at 410 nm with a 96-well microplate reader, and the elastase inhibitory activity of each sample was calculated by the following formula [4]. The results are expressed as IC ₅₀ (concentration when the percentage of inhibition of elastase activity is 50%).

Formula [4]. Elastase Inhibitory Activity (%)

= 100-[(ODs / ODc) × 100], where ODs is the absorbance at 410 nm of the experimental specimen and ODc is the absorbance at 410 nm of the untreated control.

(4) Collagenase  Inhibition assay

0.25 ml of 2 mM 4-phenylazobenzyloxycarbonyl-pro-leu-gly-pro-d-ar (Sigma-Aldrich, St. Louise, MO, USA) in 0.1M Tris-HCl buffer, pH 7.5 1.5 ml of collagenase (1 mg / ml; Sigma-Aldrich, St. Louise, Mo., USA) was added to a mixed solution of 0.1 ml of extract (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml), 37 It reacted at 20 degreeC for 20 minutes. 6% citric acid (Daejung, Seoul, Korea) was then added to stop the reaction. After adding ethyl acetate (Sigma-Aldrich, St. Louise, MO, USA), the absorbance was measured at 320 nm with UV / Vis spectrophotometer, and the collagenase inhibitory activity of each sample was calculated by the following formula [5]. .

Formula [5]. Collagenase inhibitory activity (%)

= 100-[(ODs / ODc) × 100], where ODs is the absorbance at 320 nm of the experimental specimen and ODc is the absorbance at 320 nm of the untreated control.

The results are expressed as IC ₅₀ (concentration when percentage inhibition of collagenase activity is 50%). OAs (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml) were used as standards at exactly the same experimental conditions.

(5) MMP -1 inhibition assay

20 μl of Type-I collagen (substrate; Sigma-Aldrich, St. Louise, Mo., USA) diluted with oleander fruit, gold or silver extract, or oleanolic acid as standard (0.0125, 0.025, 0.05, 0.1, 1 and 10 mg / ml) and 80 μl. Then 100 μl of diluted MMP-1 (0.2 U / ml; Sigma-Aldrich, St. Louise, Mo., USA) was added to each well and the plates were incubated for 1-2 hours at room temperature and dark conditions. Fluorescence was measured at 495 nm maximum emission and 515 nm maximum emission. All dilution procedures were performed with a reaction buffer of pH 7.6 containing 0.5M Tris-HCl, 1.5M NaCl, 50mM CaCl ₂ and 2mM sodium azide. As a control, a buffer containing substrate and inhibitor without MMP-1 was used. MMP-1 inhibitory activity of each sample was calculated by the following formula [6].

Formula [6]. MMP-1 Inhibitory Activity (%)

= 100-[(ODs / ODc) × 100], where ODs is absorbance at 515 nm of the experimental specimen and ODc is absorbance at 515 nm of the untreated control.

The results are expressed as IC ₅₀ (concentration when the percentage inhibition of MMP-1 activity is 50%).

Example  5. Whitening Effect

The whitening effect of BHcL in the present invention is compared to LFi and LFs, and arbutin as a standard, tyrosinase inhibitory assay and melanin formation test in melanoma cells B16 / F10. Measured through.

(One) Tyrosinase ( tyrosinase ) Inhibition assay

0.05 ml of BHcL, LFs or LFi (12.5, 25, 50, 100, 200 and 400 μg / ml) was mixed with 0.5 ml of L-DOPA (Sigma-Aldrich, St. Louise, MO, USA) solution (1.25 mM) and sodium acetate buffer (0.05M, pH 6.8) was mixed with 0.9ml and incubated at 25 ° C for 10 minutes. Next, 0.05 ml of an aqueous mushroom type tyrosinase (333 U / ml; Sigma-Aldrich, St. Louise, Mo., USA) was added to the mixed solution. Dopachrome formation was observed in the solution by measuring linear increase at 475 nm OD with a UV / Vis spectrophotometer, and tyrosinase inhibitory activity of each sample was calculated by the following formula [7]. The results are expressed as IC ₅₀ (concentration when the percentage inhibition of tyrosinase activity is 50%). Arbutin (10, 20, 40, 80, 160 and 320 μg / ml) was used as standard at exactly the same experimental conditions.

Formula [7]. Tyrosinase Inhibitory Activity (%)

= 100-[(ODs / ODc) × 100], where ODs is absorbance at 475 nm of the experimental specimen and ODc is absorbance at 475 nm of the untreated control

(2) Melanin Formation Test in B16 / F10 Melanoma

6-well culture plates were seeded with B16 / F10 melanoma cells at 2 × 10 ⁵ cells / well in 3 ml medium and incubated overnight to attach. The cells were treated with varying concentrations of BHcL, LFs or LFi (50, 100, 200, 400, 800) with or without 100 nM α-MSH (alpha-melanocyte stimulating hormone, Sigma-Aldrich, St. Louise, MO, USA). 1,600 μg / mL) was added and incubated for 72 hours. After treatment, the cells were washed with PBS and lysed at 800 ° C. with 800 μl of 1N NaOH (Merck, Darmstadt, Germany) containing 10% DMSO (Sigma-Aldrich, St. Louise, Mo., USA). I was. Absorbance was measured at 400 nm using a microplate reader. Melanin production inhibitory activity of each sample was calculated by the following formula [8]. The results are expressed as IC ₅₀ (concentration when the percentage of melanin production inhibition is 50%). Arbutin (20, 40, 80, 160, 320 and 640 μg / ml) was used as standard at exactly the same experimental conditions.

Formula [8]. Melanin production inhibitory activity (%)

= 100-[(ODs / ODc) × 100], where ODs is the absorbance at 400 nm of the experimental specimen and ODc is the absorbance at 400 nm of the control treated with α-MSH

Example  6. In vivo skin Moisturizing effect

In the present invention, the skin moisturizing effect of the test specimen was confirmed by measuring the change in the mouse skin moisture content.

(1) mouse breeding

316 male SPF / VAF Outbred CrljOri: CD1 [ICR] mice (6 weeks old, OrientBio, Seungnam, Korea) were used in the experiment after 7 days of adaptation. Mice were housed with 4 to 5 birds per cage in a room at 20-25 ° C. and 40-45% humidity conditions. The light: dark cycle was 12 h: 12 h and freely supplied with standard rodent feed and water during the adaptation period. After the adaptation period, the mice were divided into six groups, the group treated with LFs 0.167 mg / cm ² , LFi 0.167 mg / cm ² , and BHcL 0.017, 0.083 and 0.167 mg / cm ² locally, in total, 30 Eight mice per six timepoints of minutes, 1, 2, 4, 8 and 24 hours were selected and grouped by body weight.

(2) treatment

BHcL was dissolved in distilled water at concentrations of 1, 5 and 10 mg / ml, and LFs or LFi were dissolved in distilled water at concentrations of 10 mg / ml. Next, 100 μl of distilled water, LFs or LFi (0.167 mg / cm ² ), or three concentrations of BHcL (0.017, 0.083 and 0.167 mg / cm ² ), respectively, were applied directly to the 2x3 cm area of the dorsal skin of the mouse It was. After 30 minutes of application, all remaining samples were removed with cotton.

(3) skin moisture content measurement

After 0.5, 1, 2, 4, 8 and 24 hours from the sample application, 2x3 cm of skin was removed and the skin moisture content (%) was determined by automated moisture analyzers balance (MB23, Ohaus, Pine Brook, NJ, USA). Measured. In addition, to help understand the efficiency of the test sample, the percentage change compared to the untreated control was calculated by the following formula [9].

Formula [9]. % Change compared to untreated control

= [((Data from untreated control-data from untreated control) / data from untreated control) × 100]

Example  7. Statistical Analysis

All in vitro data are expressed as mean ± SD values of five independent experiments, and skin moisture content is expressed as mean ± SD value of 8 mouse skin at each time point. Multiple comparison tests were performed for various dose groups. Variation homogeneity was examined using the Levene test. When the Levene test results insignificant deviations from the variance homogeneity, the data obtained were analyzed by least-significant differences (LSD) multi-comparison test after one way ANOVA test to determine which group pairs in the group comparisons differ. . In addition, when a significant deviation from the homogeneity of mutation was observed in the Levene test, non-parametric comparison test and Kruskal-Wallis H test were performed. When significant differences were observed in the Kruskal-Wallis H test, the Mann-Whitney U-Wilcoxon Rank Sum W test was performed to determine specific group pairs with significantly different differences. In each in vitro assay, EC ₅₀ or IC ₅₀ values were calculated using the Probit method, and statistical analysis was performed using SPSS for Windows (Release 14.0K, SPSS Inc., Chicago, IL, USA).

Experimental Example  1. Cytotoxicity

(1) human fibroblasts

Human fibroblast viability was not significantly different compared to the untreated medium control group from the 1.25 mg / ml treatment group, the lowest treatment concentration of BHcL, LFs and LFi, to the 500 mg / ml treatment group, the highest treatment concentration (FIGS. 1A-1C).

(2) B16 / F10 Murine  Melanoma cells

The survival rate of B16 / F10 murine melanoma cells was not significantly different from the untreated medium control group from the 1.25 mg / ml treatment group of the lowest treatment concentration of BHcL, LFs and LFi to the 500 mg / ml treatment group of the highest treatment concentration (FIG. 2A). To 2c).

That is, it was confirmed that the BHcL of the present invention as well as LFs and LFi used for comparative purposes do not exhibit cytotoxicity, which suggests that BHcL can be safely used in cosmetic compositions, pharmaceutical compositions and quasi-drugs.

Experimental Example  2. Anti skin aging, skin regeneration and Hangzhou wrinkle  Check the effect

(1) Collagen Type I Synthesis Effect

Significant (p <0.01) increase in collagen type I productivity in TGF-β1, BHcL, LFs and LFi treated groups, respectively, was observed from 1 ng / ml, 0.025, 0.05 and 0.05 mg / ml compared to untreated media control, respectively. , EC ₅₀ is 20.16 ± 3.48 ng / ml (TGF-β1 group), 0.04 ± 0.03 mg / ml (BHcL group), 0.17 ± 0.07 mg / ml (LFs group) and 0.20 ± 0.10 mg / ml (LFi group) The EC ₅₀ was significantly lower in the BHcL treatment group (p <0.01 and p <0.05, respectively) than in the LFs and LFi treatment groups (p <0.01 and p <0.05, respectively). Thus, BHcL can synthesize collagen type I more effectively than LFs and LFi.

(2) hyaluronidase inhibitory activity

In the OA, BHcL, LFs and LFi treated groups, significant (p <0.01 or p <0.05) inhibition of hyaluronidase activity was recognized from 0.0125, 0.0125, 0.025 and 0.05 mg / ml, respectively, compared to the control, resulting in an IC ₅₀ of Calculated as 0.07 ± 0.05 mg / ml (OA group), 0.16 ± 0.08 mg / ml (BHcL group), 1.92 ± 0.97 mg / ml (LFs group) and 2.24 ± 1.23 mg / ml (LFi group), in particular LFs and significantly compared to the IC ₅₀ of LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 4a to 4d). Thus, BHcL can inhibit hyaluronidase activity more effectively than LFs and LFi.

(3) elastase inhibitory activity

In the PP, BHcL, LFs and LFi treated groups, significant (p <0.01) suppression of elastase activity was recognized from 1.25 ng / ml, 0.0125, 0.05 and 0.05 mg / ml, respectively, compared to the control, resulting in an IC ₅₀ of 7.72 ±. 3.69 ng / ml (PP group), 0.11 ± 0.08 mg / ml (BHcL group), 1.19 ± 0.41 mg / ml (LFs group) and 3.48 ± 2.85 mg / ml (LFi group), especially for LFs and LFi Significantly lower than IC ₅₀ (p <0.01), IC ₅₀ was recognized in the BHcL treated group (FIGS. 5A-5D). Thus, BHcL can more effectively inhibit elastase activity than LFs and LFi.

(4) Collagenase  Inhibitory activity

In the OA, BHcL, LFs and LFi treated groups, significant (p <0.01) collagenase activity inhibition was recognized from 0.0125, 0.025, 0.05 and 0.1 mg / ml compared to the control, respectively, resulting in an IC ₅₀ of 0.04 ± 0.02 mg / Ml (OA group), 0.27 ± 0.11 mg / ml (BHcL group), 4.01 ± 1.01 mg / ml (LFs group) and 21.77 ± 9.90 mg / ml (LFi group), especially for IC ₅₀ of LFs and LFi A significantly lower (p <0.01) lower IC ₅₀ was recognized in the BHcL treated group (FIGS. 6A-6D). Therefore, BHcL can inhibit collagenase activity more effectively than LFs and LFi.

(5) MMP -1 inhibitory activity

In OA, BHcL, LFs and LFi treated groups, significant (p <0.01) inhibition of MMP-1 activity was recognized from 0.025, 0.05, 0.1 and 1 mg / ml compared to the control, respectively, resulting in an IC ₅₀ of 0.38 ± 0.23 mg / Ml (OA group), 1.41 ± 0.92 mg / ml (BHcL group), 20.04 ± 10.65 mg / ml (LFs group) and 43.30 ± 13.18 mg / ml (LFi group), especially IC ₅₀ of LFs and LFi Significantly (p <0.01) lower IC ₅₀ was recognized in the BHcL treatment group (FIGS. 7A-7D), thus BHcL can more effectively inhibit the activity of MMP-1 than LFs and LFi.

Taken together, BHcL increases collagen type I synthesis and inhibits the activity of hyaluronidase, elastase, collagenase, and MMP-1, so it has excellent effects as a composition for preventing skin aging, skin regeneration and skin wrinkle improvement. have.

Experimental Example  3. Check the whitening effect

(One) Tyrosinase  Inhibitory activity

Inhibition of significant (p <0.01 or p <0.05) tyrosinase activity in Arbutin, BHcL, LFs and LFi treated groups, respectively, from 20, 25, 50 and 100 μg / ml was recognized, IC ₅₀ calculated as 74.69 ± 15.10 μg / ml (arbutin group), 124.43 ± 28.40 μg / ml (BHcL group), 244.03 ± 56.09 μg / ml (LFs group) and 421.66 ± 117.35 μg / ml (LFi group) It was able, in particular significance compared to the IC ₅₀ of the LFs and LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 8a to 8d). Thus, BHcL can inhibit tyrosinase activity more effectively than LFs and LFi.

(2) Melanin Formation in B16 / F10 Melanoma Cells

Inhibition of melanin production in Arbutin, BHcL, LFs and LFi treated groups was significantly (p <0.01 or p <0.05) B16 / F10 melanoma cells 40, 200, 200 and 400 μg / ml, respectively. IC ₅₀ was recognized as 173.67 ± 39.73 μg / ml (arbutin group), 489.27 ± 84.10 μg / ml (BHcL group), 1,032.05 ± 156.71 μg / ml (LFs group) and 1,870.05 ± 482.14 μg / ml (LFi), respectively. was calculated as the group), in particular significantly compared to the IC ₅₀ of the LFs and LFi (p <0.01) lower the IC ₅₀ was observed in BHcL treated group (Fig. 9a to 9d). Thus, BHcL can inhibit melanin production more effectively than LFs and LFi.

Taken together, BHcL inhibits tyrosinase activity and inhibits melanin formation and thus has an excellent effect as a composition for skin whitening.

Experimental Example  4. Check the skin moisturizing effect in vivo

Compared to the distilled water treatment group, the significant (p <0.01) increase in the skin moisture content, that is, the moisturizing effect, was found to be dose dependent depending on all BHcL 0.017, 0.083 and 0.167 mg / cm ² treatment groups after 30 minutes of treatment. Significant (p <0.01) increase in skin moisture content was observed in the 0.083 and 0.167 mg / cm ² treatment groups, respectively, and up to 8 hours after treatment in the 0.017 mg / cm ² treatment group, up to 24 hours after treatment. A significant (p <0.01 or p <0.05) increase in skin moisture content was observed compared to the control. In addition, significant increases in skin moisture content (p <0.01 or p <0.05) in LFs and LFi and 0.167 mg / cm ² groups were observed from 30 minutes after treatment to 8 hours after treatment, in particular 0.083 and in BHcL treatment groups of 0.167 mg / cm ² in significance bihaeseodo the LFs and LFi and 0.167 mg / cm ² applied to the group (p <0.01 or p <0.05) respectively, an increase in skin moisture content up to 24 hours post-treatment after treatment 30 minutes Admitted. Meanwhile, in the BHcL treated group of 0.017 mg / cm ² , an increase in skin moisture content similar to that of the LFs and LFi and 0.167 mg / cm ² coated groups was recognized from 30 minutes after treatment to 24 hours after treatment (FIG. 10).

In the LFs 0.167 mg / cm ² application group, the skin moisture content of 30 minutes, 1, 2, 4, 8 and 24 hours after treatment was 17.49, 26.13, 21.27, 20.72, 16.90 and 9.77%, respectively. LFi 0.167 mg / cm ² application group showed changes of 16.48, 26.16, 24.49, 20.99, 20.45 and 7.43%, respectively. In addition, the BHcL 0.167 mg / cm ² application group showed changes in skin moisture content of 33.36, 43.20, 44.60, 43.38, 43.92 and 33.94% after 30 minutes, 1, 2, 4, 8 and 24 hours of treatment, respectively, compared to the control group. , 28.19, 38.71, 40.21, 39.29, 38.11 and 33.60% in the 0.083 mg / cm ² coated group and 21.19, 28.02, 25.61, 23.82, 20.51 and 9.45% in the 0.017 mg / cm ² treated group, respectively. It became.

In conclusion, BHcL may be more effective in skin moisturizing in vivo than LFs and LFi, and may be used as a skin moisturizing composition.

From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (6)

1. Lonicera caerulea ) Cosmetic composition for preventing skin aging, skin regeneration, skin wrinkle improvement or skin moisturizing containing fruit extract as an active ingredient.
2. The composition of claim 1, wherein the dainty fruit extract is extracted with water, an organic solvent or a mixed solvent thereof.
3. The composition of claim 1, further comprising a cosmetic excipient.
4. The group of claim 1 wherein the composition consists of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray Characterized in that it has a formulation selected from.
5. Lonicera caerulea ) A pharmaceutical composition for skin regeneration comprising the fruit extract as an active ingredient.
6. Lonicera caerulea ) Quasi-drug for skin aging, skin regeneration, skin wrinkle improvement or skin moisturizing, containing fruit extract as an active ingredient.

Images